Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Qiagen (QGEN) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits

by Zacks Equity Research

The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area

Zacks Equity Research

QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure

by Zacks Equity Research

If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.

Zacks Equity Research

QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

by Zacks Equity Research

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

Zacks Equity Research

Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

by Zacks Equity Research

Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

Zacks Equity Research

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

by Zacks Equity Research

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

Zacks Equity Research

Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results

by Zacks Equity Research

The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.

Zacks Equity Research

Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

Zacks Equity Research

QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View

by Zacks Equity Research

QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.